RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAGE Therapeutics Stock

SAGE Therapeutics Liabilities 2024

SAGE Therapeutics Liabilities

82.75 M USD

Ticker

SAGE

ISIN

US78667J1088

WKN

A117WF

In 2024, SAGE Therapeutics's total liabilities amounted to 82.75 M USD, a -20.36% difference from the 103.9 M USD total liabilities in the previous year.

SAGE Therapeutics Aktienanalyse

What does SAGE Therapeutics do?

SAGE Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing SAGE Therapeutics's Liabilities

SAGE Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SAGE Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SAGE Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SAGE Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SAGE Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SAGE Therapeutics stock

What is the level of liabilities of SAGE Therapeutics this year?

SAGE Therapeutics has a debt balance of 82.75 M USD this year.

What were the liabilities of SAGE Therapeutics compared to the previous year?

The liabilities of SAGE Therapeutics have increased by -20.36% dropped compared to the previous year.

What are the consequences of high debt for investors of SAGE Therapeutics?

High liabilities can pose a risk for investors of SAGE Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in SAGE Therapeutics?

Low liabilities mean that SAGE Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of SAGE Therapeutics affect the company?

An increase in liabilities of SAGE Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of SAGE Therapeutics affect the company?

A decrease in the liabilities of SAGE Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of SAGE Therapeutics?

Some factors that can influence the liabilities of SAGE Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of SAGE Therapeutics so important for investors?

The liabilities of SAGE Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can SAGE Therapeutics take to modify the liabilities?

To change its liabilities, SAGE Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does SAGE Therapeutics pay?

Over the past 12 months, SAGE Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAGE Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAGE Therapeutics?

The current dividend yield of SAGE Therapeutics is .

When does SAGE Therapeutics pay dividends?

SAGE Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAGE Therapeutics?

SAGE Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SAGE Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAGE Therapeutics located?

SAGE Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAGE Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAGE Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did SAGE Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of SAGE Therapeutics in the year 2023?

In the year 2023, SAGE Therapeutics distributed 0 USD as dividends.

In which currency does SAGE Therapeutics pay out the dividend?

The dividends of SAGE Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAGE Therapeutics

Our stock analysis for SAGE Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAGE Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.